Because of the differences between included and excluded patients in terms of type of treatment, age at first treatment or first ADA status, our study population might not be representative of the general population of the IFNβ-treated or natalizumab-treated and ADA tested MS patients. The gene discussed is ADA; the disease is myeloid sarcoma.